Sanofi's Provention buyout hit with FTC delay. Will Pfizer's Seagen deal go off as planned?

The U.S. antitrust watchdog is taking more time to review the proposed combination of Sanofi and Provention Bio, two diabetes drug developers. Meanwhile, all eyes in biopharma are on the merger between Pfizer and Seagen.